Dupixent vs Other Biologics: Safety Questions

Biologics affect different immune pathways, and risk profiles are not identical across products. Dupixent targets IL-4/IL-13 signaling, while other biologics may target TNF, IL-17, IL-23, or other pathways.

Safety monitoring does not assume all biologics carry the same risk. Instead, it focuses on whether Dupixent-specific evidence and post-marketing signals warrant stronger warnings.

Patients comparing treatment options should discuss personal cancer history, family history, and comorbidities with their specialist.